Meeting
2019 Gastrointestinal Cancers Symposium
Comparison of neoadjuvant and adjuvant therapy for resectable pancreatic cancer using Markov decision modeling.
Authors
Minsig Choi
Stony Brook University, Stony Brook, NY
Minsig Choi , Sayaka Ishizawa , Yan Liang , Sina Rashidian , Aaron R. Sasson , Eugene Feinberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 448)
DOI
10.1200/JCO.2019.37.4_suppl.448
Abstract #
448
Poster Bd #
P8
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Survival outcomes of patients with resectable pancreatic cancer treated with upfront surgery versus neoadjuvant chemotherapy: A retrospective tertiary care center experience.
First Author: Fang Liu
Poster
2023 ASCO Annual Meeting
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.
First Author: Akhil Chawla
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
First Author: Choong-kun Lee
Poster
2021 ASCO Annual Meeting
Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
First Author: Quisette Janssen